Kyowa Kirin Demonstrates Commitment to Real-world Evidence for POTELIGEO® (mogamulizumab) at EORTC 2023.

TOKYO, September 21, 2023--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced the acceptance of an extensive programme of data to the annual meeting of the European Organisation for Research and Treatment of Cancer’s Cutaneous Lymphoma Tumour Group (EORTC-CLTG), taking place from the 21st – 23rd of September 2023 in Leiden, the Netherlands.

Related Keywords

Tokyo ,Japan ,Italy ,United States ,Netherlands ,Germany ,Portugal ,United Kingdom ,Spain ,France ,German ,French ,Klinikum Krefeld ,Stacey Minton ,Pablo Ortiz Romero ,Marie Beylot Barry ,Chalid Assaf ,Julia Scarisbrick ,Kyowa Kirin International ,Treatment Of Cancer Cutaneous Lymphoma Tumour Group ,Kyowa Kirin Co Ltd ,French Study Group Of Cutaneous Lymphoma ,Bordeaux Institute Of Oncology ,European Organisation For Research ,University Hospital Birmingham ,International Medical Affairs ,Department Of Dermatology ,Kyowa Kirin Co ,World International Observational Study Of Mogamulizumab ,Kyowa Kirin ,European Organisation ,Cutaneous Lymphoma Tumour Group ,Executive Vice President ,Bordeaux Institute ,Mycosis Fungoides ,French Study Group ,Helios Hospital ,Hospital Universitario ,Real World International Observational Study ,Adult Patients ,Mega ,Real World ,Weiden ,The Netherlands ,Systemic Therapy ,Observational Study ,